Abrocitinib and Fluconazole (Triflucan 100 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Combined CYP2C19 and CYP2C9 inhibition increases exposure to abrocitinib and active metabolites.
Clinical significance and safety
Triflucan 100 mg contains fluconazole. Abrocitinib labeling recommends avoiding medicines with moderate-to-strong inhibition of both CYP2C19 and CYP2C9, because exposure and adverse-effect risk increase. Fluconazole is directly studied; a clinician should assess alternatives rather than the patient changing treatment alone.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.